Klotho Neurosciences

Klotho Neurosciences received FDA Orphan Drug Designation for ALS therapy candidate KLTO-202, granting tax benefits, fee exemptions, and potential 7-year U.S. exclusivity. The gene therapy targets neuromuscular junctions via a proprietary delivery system to combat motor neuron degradation while enhancing protective protein expression. CEO Joseph Sinkule emphasized its scientific promise against ALS, which affects under 200,000 Americans annually with no cure. Following animal model successes, Klotho progresses manufacturing development and regulatory plans. The investigational treatment forms part of its pipeline targeting neurodegenerative diseases through its s-KL protein platform.